Global BRAF Kinase Inhibitors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 218352
  • calendar_today Published On: Nov, 2019
  • file_copy Pages: 101
  • list Pharmaceuticals and Healthcare

Scope of the Report:

The worldwide market for BRAF Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.

This report focuses on the BRAF Kinase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Array BioPharma Inc.

Novartis AG

Bayer AG

F. Hoffmann-La Roche Ltd.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Dabrafenib

Sorafenib

Vemurafenib

Encorafenib

Market Segment by Applications, can be divided into

Hospital

Medical Research Institute

Clinic

Other

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe BRAF Kinase Inhibitors product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of BRAF Kinase Inhibitors, with price, sales, revenue and global market share of BRAF Kinase Inhibitors in 2017 and 2018.

Chapter 3, the BRAF Kinase Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the BRAF Kinase Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, BRAF Kinase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe BRAF Kinase Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 BRAF Kinase Inhibitors Introduction

1.2 Market Analysis by Type

1.2.1 Dabrafenib

1.2.2 Sorafenib

1.2.3 Vemurafenib

1.2.4 Encorafenib

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Medical Research Institute

1.3.3 Clinic

1.3.4 Other

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2014-2024)

1.4.1.2 Canada Market States and Outlook (2014-2024)

1.4.1.3 Mexico Market States and Outlook (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2014-2024)

1.4.2.2 France Market States and Outlook (2014-2024)

1.4.2.3 UK Market States and Outlook (2014-2024)

1.4.2.4 Russia Market States and Outlook (2014-2024)

1.4.2.5 Italy Market States and Outlook (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2014-2024)

1.4.3.2 Japan Market States and Outlook (2014-2024)

1.4.3.3 Korea Market States and Outlook (2014-2024)

1.4.3.4 India Market States and Outlook (2014-2024)

1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2014-2024)

1.4.4.2 Egypt Market States and Outlook (2014-2024)

1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)

1.4.4.4 South Africa Market States and Outlook (2014-2024)

1.4.4.5 Turkey Market States and Outlook (2014-2024)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Array BioPharma Inc.

2.1.1 Business Overview

2.1.2 BRAF Kinase Inhibitors Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Array BioPharma Inc. BRAF Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

2.2 Novartis AG

2.2.1 Business Overview

2.2.2 BRAF Kinase Inhibitors Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis AG BRAF Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

2.3 Bayer AG

2.3.1 Business Overview

2.3.2 BRAF Kinase Inhibitors Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Bayer AG BRAF Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

2.4 F. Hoffmann-La Roche Ltd.

2.4.1 Business Overview

2.4.2 BRAF Kinase Inhibitors Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

3 Global BRAF Kinase Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

3.1 Global BRAF Kinase Inhibitors Sales and Market Share by Manufacturer (2017-2018)

3.2 Global BRAF Kinase Inhibitors Revenue and Market Share by Manufacturer (2017-2018)

3.3 Market Concentration Rate

3.3.1 Top 3 BRAF Kinase Inhibitors Manufacturer Market Share in 2018

3.3.2 Top 6 BRAF Kinase Inhibitors Manufacturer Market Share in 2018

3.4 Market Competition Trend

4 Global BRAF Kinase Inhibitors Market Analysis by Regions

4.1 Global BRAF Kinase Inhibitors Sales, Revenue and Market Share by Regions

4.1.1 Global BRAF Kinase Inhibitors Sales and Market Share by Regions (2014-2019)

4.1.2 Global BRAF Kinase Inhibitors Revenue and Market Share by Regions (2014-2019)

4.2 North America BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

4.3 Europe BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

4.4 Asia-Pacific BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

4.5 South America BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

4.6 Middle East and Africa BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

5 North America BRAF Kinase Inhibitors by Country

5.1 North America BRAF Kinase Inhibitors Sales, Revenue and Market Share by Country

5.1.1 North America BRAF Kinase Inhibitors Sales and Market Share by Country (2014-2019)

5.1.2 North America BRAF Kinase Inhibitors Revenue and Market Share by Country (2014-2019)

5.2 United States BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

5.3 Canada BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

5.4 Mexico BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

6 Europe BRAF Kinase Inhibitors by Country

6.1 Europe BRAF Kinase Inhibitors Sales, Revenue and Market Share by Country

6.1.1 Europe BRAF Kinase Inhibitors Sales and Market Share by Country (2014-2019)

6.1.2 Europe BRAF Kinase Inhibitors Revenue and Market Share by Country (2014-2019)

6.2 Germany BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

6.3 UK BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

6.4 France BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

6.5 Russia BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

6.6 Italy BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

7 Asia-Pacific BRAF Kinase Inhibitors by Country

7.1 Asia-Pacific BRAF Kinase Inhibitors Sales, Revenue and Market Share by Country

7.1.1 Asia-Pacific BRAF Kinase Inhibitors Sales and Market Share by Country (2014-2019)

7.1.2 Asia-Pacific BRAF Kinase Inhibitors Revenue and Market Share by Country (2014-2019)

7.2 China BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

7.3 Japan BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

7.4 Korea BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

7.5 India BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

7.6 Southeast Asia BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

8 South America BRAF Kinase Inhibitors by Country

8.1 South America BRAF Kinase Inhibitors Sales, Revenue and Market Share by Country

8.1.1 South America BRAF Kinase Inhibitors Sales and Market Share by Country (2014-2019)

8.1.2 South America BRAF Kinase Inhibitors Revenue and Market Share by Country (2014-2019)

8.2 Brazil BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

8.3 Argentina BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

8.4 Colombia BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

9 Middle East and Africa BRAF Kinase Inhibitors by Countries

9.1 Middle East and Africa BRAF Kinase Inhibitors Sales, Revenue and Market Share by Country

9.1.1 Middle East and Africa BRAF Kinase Inhibitors Sales and Market Share by Country (2014-2019)

9.1.2 Middle East and Africa BRAF Kinase Inhibitors Revenue and Market Share by Country (2014-2019)

9.2 Saudi Arabia BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

9.3 Turkey BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

9.4 Egypt BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

9.5 Nigeria BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

9.6 South Africa BRAF Kinase Inhibitors Sales and Growth Rate (2014-2019)

10 Global BRAF Kinase Inhibitors Market Segment by Type

10.1 Global BRAF Kinase Inhibitors Sales, Revenue and Market Share by Type (2014-2019)

10.1.1 Global BRAF Kinase Inhibitors Sales and Market Share by Type (2014-2019)

10.1.2 Global BRAF Kinase Inhibitors Revenue and Market Share by Type (2014-2019)

10.2 Dabrafenib Sales Growth and Price

10.2.1 Global Dabrafenib Sales Growth (2014-2019)

10.2.2 Global Dabrafenib Price (2014-2019)

10.3 Sorafenib Sales Growth and Price

10.3.1 Global Sorafenib Sales Growth (2014-2019)

10.3.2 Global Sorafenib Price (2014-2019)

10.4 Vemurafenib Sales Growth and Price

10.4.1 Global Vemurafenib Sales Growth (2014-2019)

10.4.2 Global Vemurafenib Price (2014-2019)

10.5 Encorafenib Sales Growth and Price

10.5.1 Global Encorafenib Sales Growth (2014-2019)

10.5.2 Global Encorafenib Price (2014-2019)

11 Global BRAF Kinase Inhibitors Market Segment by Application

11.1 Global BRAF Kinase Inhibitors Sales Market Share by Application (2014-2019)

11.2 Hospital Sales Growth (2014-2019)

11.3 Medical Research Institute Sales Growth (2014-2019)

11.4 Clinic Sales Growth (2014-2019)

11.5 Other Sales Growth (2014-2019)

12 BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.1 Global BRAF Kinase Inhibitors Sales, Revenue and Growth Rate (2019-2024)

12.2 BRAF Kinase Inhibitors Market Forecast by Regions (2019-2024)

12.2.1 North America BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.2.2 Europe BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.2.3 Asia-Pacific BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.2.4 South America BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.2.5 Middle East and Africa BRAF Kinase Inhibitors Market Forecast (2019-2024)

12.3 BRAF Kinase Inhibitors Market Forecast by Type (2019-2024)

12.3.1 Global BRAF Kinase Inhibitors Sales Forecast by Type (2019-2024)

12.3.2 Global BRAF Kinase Inhibitors Market Share Forecast by Type (2019-2024)

12.4 BRAF Kinase Inhibitors Market Forecast by Application (2019-2024)

12.4.1 Global BRAF Kinase Inhibitors Sales Forecast by Application (2019-2024)

12.4.2 Global BRAF Kinase Inhibitors Market Share Forecast by Application (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure BRAF Kinase Inhibitors Picture

Table Product Specifications of BRAF Kinase Inhibitors

Figure Global Sales Market Share of BRAF Kinase Inhibitors by Types in 2018

Please fill the form below, to recieve the report sample


+1